Management of Hepatitis E Virus (HEV) Zoonotic Transmission: Protection of Rabbits against HEV Challenge following Immunization with HEV 239 Vaccine

Peng Liu, Ren jie Du, Ling Wang*, Jian Han, Lin Liu, Yu lin Zhang, Jun ke Xia, Feng min Lu, Hui Zhuang

Department of Microbiology, School of Basic Medical Sciences, Peking University, Beijing, China

Abstract

Hepatitis E virus (HEV) constitutes a significant health burden worldwide, with an estimated approximately 33% of the world’s population exposed to the pathogen. The recent licensed HEV 239 vaccine in China showed excellent protective efficacy against HEV of genotypes 1 and 4 in the general population and pregnant women. Because hepatitis E is a zoonosis, it is also necessary to ascertain whether this vaccine can serve to manage animal sources of human HEV infection. To test the efficacy of the HEV 239 vaccine in protecting animal reservoirs of HEV against HEV infection, twelve specific-pathogen-free (SPF) rabbits were divided randomly into two groups of 6 animals and inoculated intramuscularly with HEV 239 and placebo (PBS). All animals were challenged intravenously with swine HEV of genotype 4 or rabbit HEV seven weeks after the initial immunization. The course of infection was monitored for 10 weeks by serum ALT levels, duration of viremia and fecal virus excretion and HEV antibody responses. All rabbits immunized with HEV 239 developed high titers of anti-HEV and no signs of HEV infection were observed throughout the experiment, while rabbits inoculated with PBS developed viral hepatitis following challenge, with liver enzyme elevations, viremia, and fecal virus shedding. Our data indicated that the HEV 239 vaccine is highly immunogenic for rabbits and that it can completely protect rabbits against homologous and heterologous HEV infections. These findings could facilitate the prevention of food-borne sporadic HEV infection in both developing and industrialized countries.

Introduction

Hepatitis E virus (HEV) constitutes a significant health burden worldwide, especially in regions with poor sanitation including large parts of Asia, Africa and Mexico, where it has proved to be the most or second-most important cause of acute clinical hepatitis [1]. At least four genotypes comprising a single serotype of mammalian HEV exist. Genotypes 1 and 2 exclusively infect humans and are mainly responsible for the large epidemics that have occurred in resource-limited areas where they are transmitted by water-borne and fecal–oral routes usually through contaminated water supplies. Genotypes 3 and 4 are zoonotic, and are mainly associated with sporadic infections and limited foodborne outbreaks in both developing and developed countries [2]. To-date, in addition to human, mammalian HEV strains have been isolated from both domesticated and wild pigs, sika deer, mongooses and rabbits, and antibodies to HEV have been detected in a wider range of animal species including cats, dogs, cattle, sheep, goats, horses, macaques, donkeys, rats, and mice [3,4].

Accumulating lines of evidence indicate that animal reservoirs of HEV serve as important sources of human infection. The demonstration of HEV infection in humans following consumption of undercooked infected meat from wild boar and deer has provided direct proof of zoonotic transmission of HEV genotypes 3 and 4 [5,6]. Furthermore, swine and rabbit HEVs have been shown experimentally to be capable of crossing the species barrier and infecting non-human primates [7,8]. In addition, the higher frequency of antibodies to HEV among animal handlers [9,10] and the close genetic relationship of HEV strains obtained from humans and those from swine in the same geographical regions also support zoonotic transmission is a significant route of the virus spreading [11,12]. The zoonotic nature of HEV dictates that foodborne infection can possibly be prevented through vaccination of significant animal reservoirs such as pigs and rabbits.

HEV 239 (Hecolin; Xiamen Innovax Biotech, Xiamen, China), which was approved by China’s State Food and Drug Administration (SFDA) in December 2011, is the world’s first commercial vaccine against HEV infection [13]. The results of a Phase III trial in China involving 11,165 healthy men and women aged 16–65 years showed a protective efficacy of 100% and no unexpected side effects in the general population [14] and pregnant women [15]. In the present study, we evaluated the efficacy of the HEV 239 vaccine in protecting rabbits against homologous and heterologous HEV infections, aiming to examine whether HEV 239 could serve to manage HEV transmission from its animal reservoirs.

Citation: Liu P, Du Rj, Wang L, Han J, Liu L, et al. (2014) Management of Hepatitis E Virus (HEV) Zoonotic Transmission: Protection of Rabbits against HEV Challenge following Immunization with HEV 239 Vaccine. PLoS ONE 9(1): e87600. doi:10.1371/journal.pone.0087600

Editor: Yung-Fu Chang, Cornell University, United States of America

Received October 24, 2013; Accepted December 19, 2013; Published January 30, 2014

Copyright: © 2014 Liu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Funding: This work was partially supported by the National Science Foundation of China (grant number 81271827) and Specialized Research Fund for the Doctoral Program of Higher Education (grant number 20120001110098). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

* E-mail: lingwang@bjmu.edu.cn
Materials and Methods

Ethics statement
The animal experiments were approved by the Committee of Laboratory Animal Welfare and Ethics, Peking University Health Science Center. The regulations of the review committee of Laboratory Animal Welfare and Ethics and the protocol for the review on Laboratory Animal Welfare and Ethics, Peking University Health Science Center, were followed.

HEV 239 vaccine
The HEV 239 vaccine (Hecolin; Xiamen Innovax Biotech, Xiamen, China) is a 26 kDa recombinant polypeptide corresponding to amino acid residues 368–606 of the capsid protein of a genotype 1 HEV strain [16]. The vaccine is expressed in Escherichia coli (E. coli) and vaccine doses contain 30 μg of the purified antigen in 0.5 mL buffered saline adsorbed to 0.8 mg aluminium hydroxide.

Specific-pathogen-free rabbits
Twelve, 6-week-old, specific-pathogen-free (SPF) New Zealand White rabbits were divided randomly into two groups of 6 animals, to serve as a placebo group and vaccine group, respectively. All rabbits were confirmed negative for anti-HEV antibodies by an enzyme-linked immunosorbent assay (ELISA) and individually housed in a BSL-2 facility.

Challenge viruses
A genotype 4 strain bjsw1 (pig feces, GU206559) and a rabbit strain of HEV CHN-BJ-R14 (rabbit feces, JX109834) were used as challenge viruses. A suspension [in phosphate-buffered saline (PBS, pH 7.4)] of feces containing the swine or rabbit HEV strain was prepared as a challenge pool. The clarified suspension was subsequently filtered through 0.45-μm and 0.22-μm filters. Quantification of HEV RNA in the virus inocula was determined according to the method described previously [17] and a final dilution containing 2.5 × 10⁶ copies per milliliter (mL) was immediately used for intravenous inoculation of animals.

Immunization and challenge
Rabbits in both the vaccine and placebo groups were inoculated intramuscularly on week 0, 2 and 4 with a 30 μg dose of vaccine in 0.5 ml or 0.5 ml of PBS, respectively. The 6 rabbits in each group were further divided into two subgroups of 3 animals on week 6, and then challenged intravenously with 1 mL of either the genotype 4 swine HEV or the rabbit HEV inocula described above.

Monitoring of rabbits following HEV challenge
Samples of serum and feces were collected prior to inoculation and weekly for 10 weeks after inoculation. Sera were tested immediately for levels of alanine aminotransferase (ALT) by an enzyme-linked immunosorbent assay (ELISA) and individually housed in a BSL-2 facility.

Specific-pathogen-free rabbits
Twelve, 6-week-old, specific-pathogen-free (SPF) New Zealand White rabbits were divided randomly into two groups of 6 animals, to serve as a placebo group and vaccine group, respectively. All rabbits were confirmed negative for anti-HEV antibodies by an enzyme-linked immunosorbent assay (ELISA) and individually housed in a BSL-2 facility.

Challenge viruses
A genotype 4 strain bjsw1 (pig feces, GU206559) and a rabbit strain of HEV CHN-BJ-R14 (rabbit feces, JX109834) were used as challenge viruses. A suspension [in phosphate-buffered saline (PBS, pH 7.4)] of feces containing the swine or rabbit HEV strain was prepared as a challenge pool. The clarified suspension was subsequently filtered through 0.45-μm and 0.22-μm filters. Quantification of HEV RNA in the virus inocula was determined according to the method described previously [17] and a final dilution containing 2.5 × 10⁶ copies per milliliter (mL) was immediately used for intravenous inoculation of animals.

Immunization and challenge
Rabbits in both the vaccine and placebo groups were inoculated intramuscularly on week 0, 2 and 4 with a 30 μg dose of vaccine in 0.5 ml or 0.5 ml of PBS, respectively. The 6 rabbits in each group were further divided into two subgroups of 3 animals on week 6, and then challenged intravenously with 1 mL of either the genotype 4 swine HEV or the rabbit HEV inocula described above.

Monitoring of rabbits following HEV challenge
Samples of serum and feces were collected prior to inoculation and weekly for 10 weeks after inoculation. Sera were tested immediately for levels of alanine aminotransferase (ALT) by a Hitachi Automatic Clinical Analyzer 7180 (Hitachi High-Technologies, Japan). Biochemical evidence of hepatitis was defined as a two-fold or greater increase in the post-inoculation/pre-inoculation ratio of ALT [18]. Anti-HEV antibodies in serum samples and HEV RNA in sera and feces were detected by ELISA and RT-nPCR as described elsewhere [8].

Results
Antibody responses of rabbits to the HEV 239 vaccine
Each of the rabbits vaccinated with three 30 μg doses of the HEV 239 vaccine mounted an anti-HEV response while control animals inoculated with PBS remained negative for antibodies to HEV during the 6 week pre-challenge period. The first vaccine dose induced a strong anti-HEV antibody response in the vaccinated animals, with the mean signal-to-cutoff (S/CO) value reaching 23.5 at week 2. Following the two booster immunizations at the second and fourth week, the anti-HEV titer (S/CO) increased to 27.3 at the time of challenge (Figure 1).
The HEV 239 vaccine elicited excellent immunogenicity in rabbits, as indicated by the strong anti-HEV antibody response in the immunized group (Figure 1). This is consistent with previous findings in mice and rhesus monkeys [16]. Although the first dose had induced satisfactory immune responses with S/CO value reaching 23.5 at week 2, three 30 mg doses of immunizations were carried out according to the instructions of the vaccine manufacture in this study. Consequently, additional studies should be performed to determine appropriate vaccine dosages and immunization times to make large-scale animal vaccinations much more cost effective. Besides, our results confirmed previous reports that rabbit model is able to serve as an alternative to the non-human primate models for HEV vaccine evaluation [24].

A growing body of evidence has revealed that rabbits constitute another potentially important reservoir of HEV and humans appear to be at risk of infection from rabbit HEV [8,25]. The recent investigations of HEV prevalence in rabbits from China, USA and France indicated rabbit HEVs are widespread among various breeds of rabbits [26–32]. Moreover, the demonstration that rabbit HEV can experimentally infect cynomolgus macaques [8] and SPF pigs [33] together with the identification of a human HEV strain closely related to rabbit HEV [32] has reinforced the potential zoonotic risk of this virus. However, it remains unclear whether rabbit HEV is preventable by vaccination of HEV 239, which is based on a genotype 1 strain of HEV [16]. In the present study, the HEV 239 vaccine conferred cross-protection against subsequent infections from rabbit HEV and swine HEV of genotype 4. By contrast, all six unvaccinated rabbits developed hepatitis, with liver enzyme elevations, viremia, and fecal virus shedding following challenge. Previous studies have shown that the capsid protein of rabbit HEV cross-reacted with antibodies against human and swine HEV [33] and that rabbit and human HEV belong to a single serotype [34], which might explain why the genotype 1 vaccine is highly efficacious against both rabbit HEV and swine HEV infection. In the previous study with rhesus monkeys, the vaccine could afford complete protection against a challenge dose of $10^4$ genomes and partial protection against infection with $10^7$ genomes [16]. The titer of challenge virus in this study was only $2.5 \times 10^6$ copies due to the limited amount of source material, and so additional studies will be needed to confirm that the 239 vaccine is able to protect rabbits against the higher challenge dose used in the earlier study.

In conclusion, the results from this study have demonstrated that the HEV 239 vaccine is highly immunogenic for rabbits and that it can completely protected these animals against rabbit HEV and genotype 4 HEV infections, suggesting the vaccine could serve as a candidate vaccine to manage animal sources of human HEV infection. These findings may facilitate the prevention of food-borne sporadic HEV infection in both developing and industrialized countries. Given that swine is the primary animal reservoir of HEV, future studies are warranted to evaluate the HEV 239 vaccine in the pig model.
Table 1. HEV 239 vaccine protects rabbits against challenge with $10^4$ genomic dose of rabbit HEV or swine HEV of genotype 4*.

| Groups | Rabbit ID/ Vaccine | Challenge inocula | Positive (+) or negative (−) HEV RNA detected in serum samples at indicated weeks post-challenge (wpc) | ALT (peak/pre) | Positive (+) or negative (−) HEV RNA detected in feces samples at indicated weeks post-challenge (wpc) |
|--------|--------------------|-------------------|---------------------------------------------------------------------------------------------------|---------------|---------------------------------------------------------------------------------------------------|
| [A] 3× PBS | V-1 Rabbit HEV | − − − − + + + − + − | 2.6                                                                 | − + + + + + + + + + | − − − − + + + + + + + + + + + + + + + + + + + + + + + + |
| V-2 | − − − − − − + + − − | 1.4 | − − + + + + + + + + | − − − − + + + + + + + + + + + + + + + + + + + + + + + + |
| V-3 | − − − − + + − − + − | 2.2 | − − − − − − + − − − | − − − − + + + + + + + + + + + + + + + + + + + + + + + + |
| [B] 3× PBS | V-4 Genotype 4 Swine HEV | − − − − − − − − | 2.5 | − − − − − − − − | − − − − + + + + + + + + + + + + + + + + + + + + + + + + |
| V-5 | − − − − − − − − | 2.2 | − − − − − − − − | − − − − + + + + + + + + + + + + + + + + + + + + + + + + |
| V-6 | − − − − − − − − | 2.0 | − − − − − − − − | − − − − + + + + + + + + + + + + + + + + + + + + + + + + |
| [C] 3× 30 μg | V-7 Rabbit HEV | − − − − − − − − | 0.8 | − − − − − − − − | − − − − − − − − − − − − − − − − − − − − − − − − − − |
| HEV 239 | V-8 | − − − − − − − − | 1.9 | − − − − − − − − | − − − − − − − − − − − − − − − − − − − − − − − − − − |
| V-9 | − − − − − − − − | 1.3 | − − − − − − − − | − − − − − − − − − − − − − − − − − − − − − − − − − − |
| [D] 3× 30 μg | V-10 Genotype 4 Swine HEV | − − − − − − − − | 1.0 | − − − − − − − − | − − − − − − − − − − − − − − − − − − − − − − − − − − |
| HEV 239 | V-11 | − − − − − − − − | 1.2 | − − − − − − − − | − − − − − − − − − − − − − − − − − − − − − − − − − − |
| V-12 | − − − − − − − − | 1.0 | − − − − − − − − | − − − − − − − − − − − − − − − − − − − − − − − − − − |

*HEV, hepatitis E virus; PBS, Phosphate Buffered Saline; ALT (peak/pre), peak/pre-infection ALT.

doi:10.1371/journal.pone.0087600.t001
Acknowledgments

We are grateful to Professor Malcolm A. McCrae of Warwick University, UK for proofreading the manuscript. We would also like to thank Xiamen Innovax Biotech, Xiamen, China, for supplying the HEV 239 vaccine.

References

1. Purcell RH, Emerson SU (2008) Hepatitis E: an emerging awareness of an old disease. J Hepatol 48: 504–503.
2. Hoofnagle JH, Nelson KE, Purcell RH (2012) Hepatitis E. N Engl J Med 367: 1237–1244.
3. Meng XJ (2010) Recent advances in Hepatitis E virus. J Viral Hepat 17: 153–161.
4. Dong C, Meng J, Dai X, Liang JH, Feagins AR, et al. (2011) Restricted cross-reactivity of hepatitis E virus genotypes 1 to 4 in the United States. J Clin Microbiol 49: 4164–4172.
5. Li TC, Chijiwa K, Sera N, Ishihashi T, Etch Y, et al. (2005) Hepatitis E virus transmission from wild boar meat. Emerg Infect Dis 11: 1958–1960.
6. Tei S, Kitaoka N, Tokashiki K, Mihara S (2003) Zoonotic transmission of hepatitis E virus from deer to human beings. Lancet 362: 371–373.
7. Meng XJ, Hallberg PG, Shapiro MS, Govindarajan S, Bruna JD, et al. (1998) Genetic and experimental evidence for cross-species infection by swine hepatitis E virus. J Virol 72: 9714–9721.
8. Liu P, Bu QN, Wang L, Han J, Du RJ, et al. (2013) Transmission of hepatitis E virus from rabbits to cynomolgus macaques. Emerg Infect Dis 19: 559–565.
9. Meng XJ, Wiseman B, Elvinger F, Guenette DK, Toth TE, et al. (2002) Prevalence of antibodies to hepatitis E virus in veterinarians working with swine and in normal blood donors in the United States and other countries. J Clin Microbiol 40: 117–122.
10. Chang Y, Wang L, Cao J, Zhu Y, Fu H, et al. (2009) Zoonotic risk of hepatitis E virus (HEV): A study of HEV infection in animals and humans in suburbs of Beijing. Hepatol Res 39: 1153–1158.
11. Purdy MA, Khudyakov YE (2011) The molecular epidemiology of hepatitis E virus infection. Virus Res 161: 31–39.
12. Liu P, Li L, Wang L, Bu Q, Fu H, et al. (2012) Phylogenetic analysis of 626 hepatitis E virus (HEV) isolates from humans and animals in China (1986–2011) showing genotype diversity and zoonotic transmission. Infect Genet Evol 12: 428–434.
13. Park SB (2012) Hepatitis E vaccine dynamics. Nature 491: 21–22.
14. Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, et al. (2010) Efficacy and safety of a recombinant hepatitis E virus vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 376: 895–902.
15. Wei T, Zhu FC, Huang SJ, Zhang XF, Wang ZZ, et al. (2012) Safety of the hepatitis E vaccine for pregnant women: a preliminary analysis. Hepatology 55: 2038–2040.
16. Li SW, Zhang J, Li YM, Ou SH, Huang GY, et al. (2005) A bacterially expressed particulate hepatitis E virus vaccine: antigenicity, immunogenicity and protective efficacy on primates. Vaccine 23: 2893–2901.
17. Jothikumar N, Cromeans TL, Robertson BH, Meng XJ, Hill VR (2006) A broadly reactive one-step real-time RT-PCR assay for rapid and sensitive detection of hepatitis E virus. J Virol Methods 131: 63–71.
18. Ma H, Zheng L, Liu Y, Zhao C, Harrison TJ, et al. (2010) Experimental infection of rabbits with rabbit and genotypes 1 and 4 hepatitis E viruses. PLoS ONE 5: e9160.
19. Oller L, Tielde N, Sanderson F, Heudier P, Giordanengo V, et al. (2009) Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab. Ann Intern Med 150: 450–451.
20. Kamar N, Selove J, Mansoy JM, Ouezzani L, Perou JM, et al. (2008) Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 358: 811–817.
21. Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S (2009) Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med 361: 1025–1027.
22. Dalton HR, Bendall R, Ijaz S, Banks M (2008) Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis 8: 696–709.
23. Kang M, Bendall R, Logrand-Abravanel F, Xia NS, Ijaz S, et al. (2012) Hepatitis E. Lancet 379: 2477–2488.
24. Cheng X, Wang S, Dai X, Shi C, Wen Y, et al. (2012) Rabbit as a novel animal model for hepatitis E virus infection and vaccine evaluation. PLoS One 7: e51616.
25. Lhomme S, Dubois M, Abravanel F, Top S, Bertaglioni S, et al. (2013) Risk of zoonotic transmission of HEV from rabbits. J Clin Virol.